SOPHiA GENETICS and AstraZeneca Spain expand
HRD testing program to support molecular diagnosis of ovarian
cancer in Spain
BOSTON and ROLLE, Switzerland and MADRID, Feb. 7,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a
cloud-native software company and a leader in data-driven
medicine, today announced it has expanded an existing program
in Spain to increase access to
local testing for homologous recombination deficiency (HRD)
throughout the country. The expansion of the program, supported by
AstraZeneca Spain and its network throughout the country, will
further SOPHiA GENETICS' commitment to global health equity by
making this vital testing available to thousands more patients in
the country.
The program from SOPHiA GENETICS and AstraZeneca Spain started
in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to
deploy HRD testing to five labs throughout the country. In just six
weeks on average, the labs were ready to start processing samples,
allowing them to process tumor samples in an expedient manner. This
collaboration allowed for over 4,000 samples to be analyzed
to-date, equating to approximately 90 percent of HRD testing
available for patients in Spain.
With today's announcement, AstraZeneca Spain named SOPHiA
GENETICS its preferred partner in deploying HRD testing throughout
Spain. Together, SOPHiA GENETICS
and AstraZeneca are offering the option for HRD testing to become
available to even more laboratories throughout the country to help
facilitate in-house HRD detection. The testing will not only aid in
identifying HRD-positive tumors but will support faster diagnostics
by increasing the volume and speed of next-generation sequencing
(NGS) testing and tumor profiling available. By deploying the
SOPHiA DDM™ Platform across further labs, the companies aim to
increase accelerated diagnostics for patients and support
clinicians in precision treatment planning.
For Marta Moreno, director of
Corporate Affairs and Market Access of AstraZeneca Spain, "At
AstraZeneca we are focused on putting the medicine precision
available to patients collaborating with hospitals and reference
centers throughout Spain. Thanks
to the study of biomarkers we can improve the approach to cancer
patients, giving them treatment with greater guarantee of
effectiveness and as personalized as possible, complying with
our goal of chronicling cancer and getting rid of it someday as a
cause of death. Hence our agreement with SOPHiA GENETICS, to offer
hospital centers throughout Spain
the possibility of making an accurate diagnosis for patients with
ovarian cancer."
"The ability for local facilities in Spain to test for HRD status is paramount to
providers in the region developing data-driven treatment plans to
help increase positive health outcomes," said Kevin Puylaert,
Managing Director, EMEA, SOPHiA GENETICS. "We are excited to expand
our testing program across several local diagnostic facilities.
This program will not only make a difference to those who receive
testing but will increase the volume of global data on HRD to help
further progress on treatment options for those facing ovarian
cancer."
HRD is caused by a cell's impaired ability to repair DNA
double-stranded breaks through the homologous recombination repair
(HRR) pathway; it is an important predictor of tumor response to
certain treatment options. HRD is linked with the development of
several cancers, including advanced ovarian cancer, and is the most
prevalent alteration in ovarian cancer1, with
approximately half of all newly diagnosed patients having
HRD-positive tumors2.
About AstraZeneca Spain
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company focused on the discovery, development and
commercialization of prescription medicines in Oncology, Rare
Diseases and Biopharma, including Cardiovascular, Renal and
Metabolism, and Respiratory and Immunology. Headquartered in
Cambridge, United Kingdom,
AstraZeneca operates in more than 100 countries and its
innovative medicines are used by millions of patients around the
world.
AstraZeneca is a Top Employers in Spain and Europe and has been awarded the EFR
certificate for a Family Responsible Company.
Visit astrazeneca.es and follow the company on Twitter
@AstraZenecaES and Instagram @AstraZenecaES
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products, and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA DDM™ Dx HRD Solution is available as a CE-IVD
product for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release
is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval
or market clearance by a governmental regulatory body for different
indications for use. Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342032/#:~:text=According%20to%20The%20Cancer%20Genome,clinical%20benefits%20of%20PARP%20inhibitors.
2https://www.sciencedirect.com/science/article/pii/S0923753421048286
Logo -
https://mma.prnewswire.com/media/1673202/4535017/SOPHiA_GENETICS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sophia-genetics-and-astrazeneca-spain-commit-to-increasing-ovarian-cancer-testing-in-spain-302056022.html